EXACT Sciences (NASDAQ:EXAS) had its price objective increased by Goldman Sachs Group to $75.00 in a research note published on Thursday, The Fly reports. Goldman Sachs Group currently has a neutral rating on the medical research company’s stock.

Several other brokerages also recently commented on EXAS. BTIG Research raised their price objective on EXACT Sciences from $60.00 to $70.00 and gave the stock a buy rating in a research note on Wednesday, May 30th. BidaskClub raised EXACT Sciences from a buy rating to a strong-buy rating in a research note on Thursday, June 7th. Leerink Swann reaffirmed an outperform rating and set a $76.00 price objective (up previously from $67.00) on shares of EXACT Sciences in a research note on Wednesday, July 18th. Jefferies Financial Group dropped their price objective on EXACT Sciences from $60.00 to $57.00 and set a buy rating on the stock in a research note on Thursday, August 2nd. Finally, Robert W. Baird raised their price objective on EXACT Sciences from $65.00 to $74.00 and gave the stock an outperform rating in a research note on Thursday, August 23rd. Three investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. EXACT Sciences has a consensus rating of Buy and an average target price of $75.18.

Shares of EXACT Sciences stock opened at $75.57 on Thursday. The firm has a market cap of $9.22 billion, a P/E ratio of -76.33 and a beta of 1.00. EXACT Sciences has a 12 month low of $37.36 and a 12 month high of $76.16. The company has a debt-to-equity ratio of 0.87, a quick ratio of 15.37 and a current ratio of 15.79.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, August 1st. The medical research company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. The business had revenue of $102.89 million for the quarter, compared to the consensus estimate of $104.40 million. EXACT Sciences had a negative return on equity of 20.10% and a negative net margin of 35.24%. The firm’s revenue was up 78.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.27) EPS. analysts expect that EXACT Sciences will post -1.35 EPS for the current year.

In other EXACT Sciences news, CFO Jeffrey Thomas Elliott sold 8,984 shares of the stock in a transaction dated Monday, July 30th. The stock was sold at an average price of $57.78, for a total transaction of $519,095.52. Following the completion of the transaction, the chief financial officer now owns 22,690 shares in the company, valued at approximately $1,311,028.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael S. Wyzga sold 2,468 shares of the stock in a transaction dated Tuesday, August 28th. The stock was sold at an average price of $74.85, for a total value of $184,729.80. Following the transaction, the director now owns 9,112 shares of the company’s stock, valued at approximately $682,033.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,014 shares of company stock valued at $1,031,717. Corporate insiders own 3.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sandy Spring Bank grew its holdings in shares of EXACT Sciences by 50.2% in the 1st quarter. Sandy Spring Bank now owns 4,672 shares of the medical research company’s stock valued at $188,000 after acquiring an additional 1,562 shares in the last quarter. Xact Kapitalforvaltning AB grew its holdings in shares of EXACT Sciences by 9.8% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 17,925 shares of the medical research company’s stock valued at $1,072,000 after acquiring an additional 1,600 shares in the last quarter. M&T Bank Corp grew its holdings in shares of EXACT Sciences by 12.7% in the 1st quarter. M&T Bank Corp now owns 16,309 shares of the medical research company’s stock valued at $658,000 after acquiring an additional 1,839 shares in the last quarter. Palo Alto Investors LP grew its holdings in shares of EXACT Sciences by 0.6% in the 1st quarter. Palo Alto Investors LP now owns 312,719 shares of the medical research company’s stock valued at $12,612,000 after acquiring an additional 1,843 shares in the last quarter. Finally, Nicolet Bankshares Inc. grew its holdings in shares of EXACT Sciences by 16.5% in the 1st quarter. Nicolet Bankshares Inc. now owns 14,125 shares of the medical research company’s stock valued at $570,000 after acquiring an additional 2,000 shares in the last quarter. Institutional investors own 86.35% of the company’s stock.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers

The Fly

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.